Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

center dot Antiretroviral protease inhibitors such as lopinavir and saquinavir have been shown to be substrates of ABCB1. Co-administration with the potent ABCB1 and CYP3A4 inhibitor, ritonavir, has shown improved pharmacokinetics and subsequent therapeutic effects of protease inhibitors. Darunavir is a recently licensed protease inhibitor with potent antiretroviral effects but has yet to be characterized as a potential substrate for drug transporters.


Published in:
British Journal Of Clinical Pharmacology, 68, 375-380
Year:
2009
Keywords:
Laboratories:




 Record created 2010-11-30, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)